Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G 1-modulated P53 activity

Hepatology

Volumn 55, Issue 3, 2012, Pages 730-741

  Wang, Saifeng ^a   Qiu, Lipeng ^a   Yan, Xiaoli ^a   Jin, Wensong ^a   Wang, Yanzhong ^a   Chen, Lizhao ^a   Wu, Erjie ^a   Ye, Xin ^a   Gao, George F ^a   Wang, Fusheng ^b   Chen, Yu ^c   Duan, Zhongping ^c   Meng, Songdong ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b BEIJING 302 HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN G1; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LUCIFERASE; MICRORNA; MICRORNA 122; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LIVER NECROSIS; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN G1; DNA, VIRAL; DOWN-REGULATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MICRORNAS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VIRAL LOAD; VIRUS REPLICATION;

EID: 84863116887     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24809     Document Type: Article

References (38)

1. Ferir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 2008; 18: 19-34.
2. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010; 52: 594-604.
3. Tan AT, Loggi E, Boni C, Chia A, Gehring AJ, Sastry KS, et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 2008; 82: 10986-10997.
4. Tang H, McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci U S A 2001; 98: 1841-1846.
5. Buhlmann S, Racek T, Schwarz A, Schaefer S, Putzer BM. Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis. J Mol Biol 2008; 378: 20-30.
6. Zheng Y, Li J, Ou JH. Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J Virol 2004; 78: 6908-6914.
7. Lin YC, Hsu EC, Ting LP. Repression of hepatitis B viral gene expression by transcription factor nuclear factor-kappaB. Cell Microbiol 2009; 11: 645-660.
8. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. HEPATOLOGY 2009; 50: 1392-1402.
9. Doitsh G, Shaul Y. Enhancer I predominance in hepatitis B virus gene expression. Mol Cell Biol 2004; 24: 1799-1808.
10. Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepatol 2010; 17: 527-536.
11. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
12. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009; 10: 578-585.
13. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656.
14. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027.
15. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Lin CW, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. HEPATOLOGY 2009; 49: 1571-1582.
16. Norman KL, Sarnow P. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J Virol 2010; 84: 666-670.
17. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. HEPATOLOGY 2010; 52: 1431-1442.
18. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300-3310.
19. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM, et al. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 2008; 82: 8215-8223.
20. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010; 84: 6615-6625.
21. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
22. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs.' Nature 2005; 438: 685-689.
23. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
24. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099.
25. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, S. Sabbioni, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767.
26. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007; 133: 1166-1174.
27. Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res 2011; 41: 46-53.
28. Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008; 23: 1419-25.
29. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-455.
30. Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010; 398: 771-777.
31. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15: 31-33.
32. Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS, et al. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 2002; 9: 761-771.
33. Piscopo DM, Hinds PW. A role for the cyclin box in the ubiquitin-mediated degradation of cyclin G1. Cancer Res 2008; 68: 5581-5590.
34. Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J 1998; 17: 544-553.
35. Soond SM, Barry SP, Melino G, Knight RA, Latchman DS, Stephanou A. p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1. Cell Cycle 2008; 7: 1214-1223.
36. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-680.
37. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449: 919-922.
38. Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. HEPATOLOGY 2010; 52: 1702-1712.